MetaCap

Oculis (OCS) vs Prothena (PRTA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Prothena (PRTA) has outperformed Oculis (OCS) over the past year, losing 21.6% versus a loss of 63.3%. Over five years, OCS leads with a -27.3% price change compared with -83.3% for PRTA. Prothena is the larger company by market cap ($422.1 million vs $393.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

OCS-63.34%PRTA-21.56%
+76%+2%-71%
Nov 21, 20251 yearNov 20, 2026
OCS-27.66%PRTA-86.00%
+251%+71%-109%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

OCS versus PRTA key metrics
MetricOCSPRTA
Share price$7.06$8.22
Market cap$393.35M$422.10M
1-day change-5.11%-2.14%
YTD return-64.65%-13.93%
1-year return-63.34%-21.56%
5-year return-27.29%-83.28%
EPS (TTM)$-1.69$-0.45
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$9.68M
Revenue growth (YoY)—-92.83%
Net income (latest FY)—$-244.09M
Operating margin—-2216.44%
Net margin—-2520.57%
52-week high$34.48$11.80
52-week low$6.78$7.70
Distance from 52-week high-79.52%-30.34%
Analyst consensusstrong_buybuy
Avg. price target upside+407.79%+160.34%
Average volume272.83K487.91K
Shares outstanding55.72M51.35M
Employees6067
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PRTA has outperformed OCS by 41.8 percentage points over the past year.

About Oculis

OCS stock →

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.

Health Care · Biotechnology: Pharmaceutical Preparations · 60 employees

About Prothena

PRTA stock →

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies.

Health Care · Biotechnology: Pharmaceutical Preparations · 67 employees

OCS vs PRTA FAQ

Which is bigger, Oculis or Prothena?

Prothena (PRTA) is larger, with a market capitalization of $422.10M compared with $393.35M for Oculis (OCS).

Which stock has performed better over the past year, OCS or PRTA?

PRTA returned -21.56% over the past 12 months, compared with -63.34% for OCS (price return, excluding dividends). Past performance does not predict future results.

Are Oculis and Prothena in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons